ArticleCureus2025
Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in adults with cystic fibrosis (CF). Traditional management relied on insulin therapy to counter the rise in glucose related to a carbohydrate-rich diet, which was previously recommended. Disease-modifying therapies for CF have, however, changed the metabolic milieu, and we are seeing rising rates of people with CF experiencing weight gain and developing metabolic syndrome. This calls for a paradigm shift in managing CFRD. We describe a 51-year-old woman with long-standing CFRD who, despite basal-bolus insulin, had suboptimal glycaemic control and emerging cardiovascular risk factors. After initiation of tirzepatide, she experienced improved glucose control, HbA1c, weight and blood pressure over three months without major adverse effects. This case illustrates the potential of tirzepatide to address both glycaemic and cardiometabolic risk in CFRD and highlights the need for formal evaluation of GLP-1/GIP receptor agonists in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.